BFG
ALNY icon

Bleakley Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bleakley Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,590
Closed -$610K – 524
2024
Q4 		$610K Buy
2,590
+375
+17% +$98.6K 0.02% 562
2024
Q3 		$609K Buy
2,215
+439
+25% +$114K 0.02% 540
2024
Q2 		$432K Sell
1,776
-162
-8% -$25.6K 0.01% 650
2024
Q1 		$290K Sell
1,938
-88
-4% -$14.7K 0.01% 769
2023
Q4 		$388K Buy
2,026
+404
+25% +$68.8K 0.01% 656
2023
Q3 		$287K Sell
1,622
-234
-13% -$44.6K 0.01% 698
2023
Q2 		$353K Buy
1,856
+147
+9% +$29.1K 0.01% 680
2023
Q1 		$342K Sell
1,709
-197
-10% -$41.4K 0.01% 671
2022
Q4 		$453K Buy
+1,906
New +$407K 0.02% 575

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bleakley Financial Group's ALNY Position: Q1 2025 in Review

Bleakley Financial Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 2,590 shares — an estimated $610K sold.

Bleakley Financial Group first reported a position in ALNY in Q4 2022 and held it in 9 quarters. The position peaked at $610K in Q4 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

  • Bleakley Financial Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Bleakley Financial Group sold 2,590 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $610K.
  • Bleakley Financial Group first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • Bleakley Financial Group's Alnylam Pharmaceuticals position peaked at $610K in Q4 2024.
  • 627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Bleakley Financial Group's 13F filing for Q1 2025, filed 1 May 2025.